Related Experiment Video

Updated: Jun 26, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.6K

Factor XI Inhibitors: perspectives in primary and secondary prevention of ischemic stroke

Domenico Prisco1,2, Maria Canfora3, Matteo Mazzetti2

  • 1Department of Experimental and Clinical Medicine, University of Florence, Viale L.Go Giovanni Brambilla, 3, 50134, Florence, Italy.

Internal and Emergency Medicine
|May 14, 2024
PubMed

Insights

New Factor XI (FXI) inhibitors offer a novel anticoagulant approach to prevent stroke. These agents target the coagulation contact pathway, addressing unmet needs in stroke prevention and bleeding risk.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Neurology

Background:

  • Stroke is a leading cause of death and disability globally.
  • Antithrombotic therapies, including anticoagulants and antiplatelets, are crucial for stroke prevention.
  • Current treatments face limitations regarding residual risk and bleeding complications.

Purpose of the Study:

  • To review the evidence and future prospects of Factor XI (FXI) inhibitors.
  • To explore FXI inhibitors as a novel anticoagulant strategy for stroke prevention.
  • To evaluate their potential in managing cardioembolic and non-cardioembolic ischemic stroke.

Main Methods:

  • Review of current scientific literature on FXI and FXII inhibitors.
  • Analysis of the selective inhibition of the coagulation contact pathway.
  • Examination of therapeutic implications for stroke prevention.

Main Results:

  • Factor XI (FXI) and Factor XII inhibitors represent a new class of anticoagulants.
  • Selective inhibition of the contact pathway offers a targeted approach.
  • These agents show promise in addressing limitations of existing antithrombotic therapies.

Conclusions:

  • FXI inhibitors may offer an additional therapeutic option for ischemic stroke prevention.
  • They hold potential for both primary and secondary prevention in various stroke types.
  • Further research is needed to establish their role in challenging clinical scenarios.

Keywords:
AnticoagulantsAtrial fibrillationFactor XI inhibitorsStroke

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K
Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.6K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
686
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
521
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.2K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.6K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167